Next, we quantified MC38 tumor-specific cytotoxic T cells using MC38 tumor dominant epitope (KSPWFTTL-H-2Kb (KSP) peptide) tetramer, and found that the proportion of MC38 tumor-specific CD8+ T cells increased by 1.8-fold within LP-treated (figure 2D). The gene discussed is CD8A; the disease is neoplasm.